Mutual alteration of NOD2-associated Blau syndrome and IFNγR1 deficiency
暂无分享,去创建一个
J. Casanova | E. Froňková | A. Šedivá | Z. Parackova | P. Vrabcová | M. Svatoň | A. Klocperk | M. Bloomfield | T. Milota | J. Bustamante | Irena Zentsova
[1] B. Grimbacher,et al. What did we learn from CTLA‐4 insufficiency on the human immune system? , 2018, Immunological reviews.
[2] J. Casanova,et al. Tuberculosis and impaired IL-23–dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant , 2018, Science Immunology.
[3] J. Casanova,et al. Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23 , 2018, Science Immunology.
[4] O. Elemento,et al. Phenotype, penetrance, and treatment of 133 cytotoxic T‐lymphocyte antigen 4–insufficient subjects , 2018, The Journal of allergy and clinical immunology.
[5] J. Casanova,et al. Mendelian susceptibility to mycobacterial disease: 2014–2018 update , 2018, Immunology and cell biology.
[6] J. Casanova,et al. A purely quantitative form of partial recessive IFN‐&ggr;R2 deficiency caused by mutations of the initiation or second codon , 2018, Human molecular genetics.
[7] J. Casanova,et al. Disruption of an anti-mycobacterial circuit between dendritic and Th cells in human SPPL2a deficiency , 2018, Nature Immunology.
[8] L. Stronati,et al. NOD2 and inflammation: current insights , 2018, Journal of inflammation research.
[9] C. Foster,et al. A Novel NOD2-associated Mutation and Variant Blau Syndrome: Phenotype and Molecular Analysis , 2018, Ocular immunology and inflammation.
[10] N. Kanazawa,et al. A Case of Blau Syndrome with NOD2 E383K Mutation , 2016, Pediatric dermatology.
[11] Huy A. Nguyen,et al. Role for NOD2 in Mycobacterium tuberculosis‐induced iNOS expression and NO production in human macrophages , 2015, Journal of leukocyte biology.
[12] P. Tighe,et al. Ex vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome. , 2015, Reumatismo.
[13] H. Rosenzweig,et al. Blau Syndrome–Associated Nod2 Mutation Alters Expression of Full-Length NOD2 and Limits Responses to Muramyl Dipeptide in Knock-in Mice , 2015, The Journal of Immunology.
[14] J. Casanova,et al. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. , 2014, Seminars in immunology.
[15] J. Bertin,et al. Blau Syndrome, the prototypic auto-inflammatory granulomatous disease , 2014, Pediatric Rheumatology.
[16] Y. Ohya,et al. Augmentation of antitubercular therapy with IFNγ in a patient with dominant partial IFNγ receptor 1 deficiency. , 2014, Clinical immunology.
[17] D. Philpott,et al. NOD proteins: regulators of inflammation in health and disease , 2013, Nature Reviews Immunology.
[18] A. Cava. Common variable immunodeficiency: two mutations are better than one , 2013 .
[19] R. Xavier,et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes , 2012, Proceedings of the National Academy of Sciences.
[20] Jianping Xie,et al. NOD2 Signaling and Role in Pathogenic Mycobacterium Recognition, Infection and Immunity , 2012, Cellular Physiology and Biochemistry.
[21] Pablo Cingolani,et al. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift , 2012, Front. Gene..
[22] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[23] C. Wouters,et al. Blau syndrome revisited , 2011, Current opinion in rheumatology.
[24] Murugesan V. S. Rajaram,et al. NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages , 2011, Cellular microbiology.
[25] Chan-Wook Woo,et al. Altered cytokine profiles of mononuclear cells after stimulation in a patient with Blau syndrome , 2010, Rheumatology International.
[26] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[27] C. Wouters,et al. Incomplete penetrance of the NOD2 E383K substitution among members of a pediatric granulomatous arthritis pedigree. , 2009, Arthritis and rheumatism.
[28] J. Yagüe,et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. , 2009, Arthritis and rheumatism.
[29] J. Rosenbaum,et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. , 2009, Arthritis and rheumatism.
[30] A. Smahi,et al. TLR3 Deficiency in Patients with Herpes Simplex Encephalitis , 2007, Science.
[31] J. Casanova,et al. Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features , 2006 .
[32] J. Casanova,et al. Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease , 2006, PLoS genetics.
[33] M. Netea,et al. NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis , 2005, PLoS pathogens.
[34] S. Holland,et al. Defects in the interferon‐γ and interleukin‐12 pathways , 2005, Immunological reviews.
[35] M. Newport,et al. Clinical features of dominant and recessive interferon γ receptor 1 deficiencies , 2004, The Lancet.
[36] A. Utani,et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. , 2004, Blood.
[37] E. Mallon,et al. Juvenile sarcoidosis after BCG vaccination. , 2003, Journal of the American Academy of Dermatology.
[38] P. Rosenstiel,et al. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells ☆ ☆☆ ★ ★★ ♢ , 2003 .
[39] M. Chamaillard,et al. Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.
[40] J. Blackwell,et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies , 2002, The Lancet.
[41] G. Thomas,et al. CARD15 mutations in Blau syndrome , 2001, Nature Genetics.
[42] J. Casanova,et al. High Levels of Interferon Gamma in the Plasma of Children With Complete Interferon Gamma Receptor Deficiency , 2001, Pediatrics.
[43] J. Casanova,et al. Interferon-γ receptor deficiency: An expanding clinical phenotype? , 1999 .
[44] S. Dorman,et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection , 1999, Nature Genetics.
[45] J. Casanova,et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. , 1997, The Journal of clinical investigation.
[46] J. Casanova,et al. CORRELATION OF GRANULOMA STRUCTURE WITH CLINICAL OUTCOME DEFINES TWO TYPES OF IDIOPATHIC DISSEMINATED BCG INFECTION , 1997, The Journal of pathology.
[47] M. Newport,et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. , 1996, The New England journal of medicine.
[48] U. Andersson,et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. , 1991, Blood.
[49] T. Nakahata,et al. Pluripotent stem cell models of Blau syndrome reveal an IFN‐&ggr;–dependent inflammatory response in macrophages , 2018, The Journal of allergy and clinical immunology.
[50] P. Arkwright. Phenotype, penetrance, and treatment of 133 CTLA-1 4-insufficient individuals , 2018 .
[51] G. Keskindemirci,et al. Coexistence of early onset sarcoidosis and partial interferon-γ receptor 1 deficiency. , 2016, The Turkish journal of pediatrics.
[52] J. Bertin,et al. Blau syndrome : cross-sectional data from a multicentre study of clinical , radiological and functional outcomes , 2015 .
[53] A. Fischer,et al. Immune deficiencies , infection , and systemic immune disorders Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2 – related disorders Blau syndrome and Crohn disease , 2012 .
[54] T. Nakahata,et al. A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. , 2010, Rheumatology.
[55] T. Nakahata,et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. , 2009, Arthritis and rheumatism.
[56] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..
[57] J. Casanova,et al. Interferon-gamma receptor deficiency: An expanding clinical phenotype? , 1999, Jornal de Pediatria.